Physician profile
Danielle Joy Brown
NPI 1790344570
$3,126.13
in general payments reported to CMS, 2019-2025
29 companies · $670 in 2025
The $670 reported for 2025 was more than what 97% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $943 · 2022: $807 · 2023: $369 · 2024: $337 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $71.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.63 |
| Education | $71.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.78 | 2021-2025 | |
| Pfizer INC. | $229.25 | 2021-2025 | |
| Astellas Pharma US INC | $204.34 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $151.03 | 2021-2025 | |
| Biogen, INC. | $149.24 | 2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $140.14 | 2022 | |
| Millicent US INC | $113.08 | 2021-2025 | Femring, Intrarosa |
| Amgen INC. | $106.33 | 2023-2025 | Evenity, Prolia, Prolia |
| Exeltis, USA INC. | $102.39 | 2023-2025 | Slynd |
| Mylan Pharmaceuticals INC. | $80.56 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $70.36 | 2021 | |
| Novo Nordisk INC | $69.59 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $65.51 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $60.35 | 2021-2022 | |
| Boston Scientific Corporation | $52.79 | 2022-2025 | Opticross 35 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $51.67 | 2025 | |
| Evofem Biosciences, INC. | $43.73 | 2022-2023 | Phexxi |
| Organon LLC | $40.57 | 2024 | |
| Daiichi Sankyo INC. | $37.39 | 2022 | |
| Lilly USA, LLC | $35.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.76 | 2021-2022 | |
| Therapeuticsmd, INC. | $31.52 | 2021-2022 | |
| Shield Therapeutics INC | $24.31 | 2024 | |
| Janssen Biotech, INC. | $22.75 | 2025 | Tremfya |
| Exact Sciences Corporation | $18.91 | 2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $18.78 | 2022 | |
| Optumhealth Care Solutions, LLC | $18.54 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Aspira Women'S Health INC | $17.27 | 2021 | |
| Olympus America INC. | $15.61 | 2025 | Endoclot Phs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.